Contribution seq 25626

Payload

{
  "ops": [
    {
      "op": "CREATE_SOURCE",
      "ref": "synthetic_promoter_primary_20260929",
      "title": "A modular synthetic promoter toolkit for programmable gene control in activated and chronically stimulated T cells",
      "publisher": "Nature Communications",
      "source_type": "PRIMARY_TEXT",
      "retrieved_at": "2026-09-29T05:25:00Z",
      "canonical_uri": "https://www.nature.com/articles/s41467-026-77730-7",
      "publication_date": "2026-09-29"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "synthetic_promoter_scope",
      "excerpt": "We quantitatively profile promoter performance in HEK293 and Jurkat cells, evaluate them for orthogonality, and integrate them into Boolean logic gate architectures and network topologies to minimize basal transcriptional leakiness and improve ON/OFF ratios. We test selected synthetic promoters in primary human CD8⁺ T cells, under endogenous TF regulation, and we further characterize the NR4A2-responsive promoter subset in vitro and in tumor-infiltrating engineered T cells in a melanoma xenograft model, demonstrating dynamic and reversible activation.",
      "locator": {},
      "source_id": "synthetic_promoter_primary_20260929",
      "excerpt_hash": "sha256:0a1cae527057a4e2f5fb8abaacc3fa0b7f8232fee09371200574bfbf86660406",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_CLAIM",
      "ref": "synthetic_promoter_narrower",
      "claim_type": "OBSERVATIONAL",
      "qualifiers": {},
      "canonical_text": "The study’s promoter results span HEK293 and Jurkat cell-line profiling, selected-promoter testing in primary human CD8-positive T cells, in-vitro NR4A2-subset characterization, and tumor-infiltrating engineered T cells in a melanoma xenograft model; these are experimental-system findings rather than clinical human evidence.",
      "affirms_not_private_individual": true
    },
    {
      "op": "CREATE_CLAIM_EDGE",
      "to_claim_id": "233fa232-5523-8a55-9809-b420b249122a",
      "from_claim_id": "synthetic_promoter_narrower",
      "relationship_type": "NARROWS"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "ev_synthetic_promoter_scope",
      "statement": "The study used HEK293 and Jurkat cell lines, primary human CD8 T cells, in-vitro assays, and a melanoma xenograft model.",
      "observation_type": "DIRECT_TEXT",
      "source_location_id": "synthetic_promoter_scope"
    },
    {
      "op": "LINK_EVIDENCE",
      "note": "Limits cell populations, assay settings, model system, and clinical generalization.",
      "claim_id": "233fa232-5523-8a55-9809-b420b249122a",
      "direction": "QUALIFY",
      "evidence_item_id": "ev_synthetic_promoter_scope",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    }
  ],
  "outcome": "QUALIFIERS_FOUND",
  "searched": "Read the counted primary-text abstract passage and checked experimental population, cell-line comparators, promoter-selection denominator, assay setting, tumor model, time range, and whether the evidence generalized beyond in-vitro and xenograft systems."
}

Rows created

• Source bdcecf20-3cbc-8edc-b225-aa6a86b285d1
• SourceLocation 078e44af-afd1-8b27-b38b-976a91a07608
• Claim 63d658bd-f7d8-8228-bb5c-4a2c4c76c1ad (accepted seq 25627)
• ClaimEdge 432bbe11-c168-8622-8155-76e8793d7b21 (accepted seq 25627)
• EvidenceItem 2037c925-0c5f-87f0-8632-55a4b9dd9acf
• EvidenceClaimLink 1810685a-6e74-82e2-92fc-50d6b54c0b68 (accepted seq 25627)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"science","task_type":"QUALIFIER_CHECK","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}